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Abstract
Neuroblastoma is an embryonic tumor arising from immature sympathetic nervous system cells. Recurrent genomic
alterations include MYCN and ALK amplification as well as recurrent patterns of gains and losses of whole or large partial
chromosome segments. A recent whole genome sequencing effort yielded no frequently recurring mutations in genes
other than those affecting ALK. However, the study further stresses the importance of DNA copy number alterations in this
disease, in particular for genes implicated in neuritogenesis. Here we provide additional evidence for the importance of
focal DNA copy number gains and losses, which are predominantly observed in MYCN amplified tumors. A focal 5 kb gain
encompassing the MYCN regulated miR-17,92 cluster as sole gene was detected in a neuroblastoma cell line and further
analyses of the array CGH data set demonstrated enrichment for other MYCN target genes in focal gains and
amplifications. Next we applied an integrated genomics analysis to prioritize MYCN down regulated genes mediated by
MYCN driven miRNAs within regions of focal heterozygous or homozygous deletion. We identified RGS5, a negative
regulator of G-protein signaling implicated in vascular normalization, invasion and metastasis, targeted by a focal
homozygous deletion, as a new MYCN target gene, down regulated through MYCN activated miRNAs. In addition, we
expand the miR-17,92 regulatory network controlling TGFß signaling in neuroblastoma with the ring finger protein 11
encoding gene RNF11, which was previously shown to be targeted by the miR-17,92 member miR-19b. Taken together,
our data indicate that focal DNA copy number imbalances in neuroblastoma (1) target genes that are implicated in MYCN
signaling, possibly selected to reinforce MYCN oncogene addiction and (2) serve as a resource for identifying new
molecular targets for treatment.
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Introduction
Neuroblastoma is an embryonal tumor arising from sympathetic
neuronal progenitor cells and is responsible for 15% of all pediatric
cancer deaths. This tumor exhibits a remarkably diverse clinical
behavior ranging from spontaneous regression to aggressive
disease, often refractory to multi-modal therapies [1]. Chromo-
somal and array comparative genomic hybridization (CGH) have
been particularly instrumental in uncovering portraits of DNA
copy number changes and allowed to establish a classification
model consisting of three major genomic subtypes (termed subtype
1, 2A and 2B) predictive for clinical behavior [2–4]. Apart from
the frequently occurring (large) DNA copy number alterations
such as 17q gains and 1p, 3p and 11q deletions, the discoveries of
rare focal genomic imbalances targeting ALK and NF1 [5–10] and
more recently also several genes implicated in neuritogenesis [11]
have shown that such focal DNA copy number alterations mark
important genes involved in neuroblastoma pathogenesis.
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We recently identified the miR-17,92 cluster as an important
mediator of MYCN signaling in neuroblastoma with several
components of this cluster down regulating expression of target
genes such as DKK3 and members of the TGFb pathway that
contribute to the MYCN driven tumor phenotype [12]. Here we
describe for the first time a focal 5 kb gain targeting exclusively
the miR-17,92 polycistron in a neuroblastoma cell line. Further
analyses of a large series of neuroblastoma tumors and cell lines
(n = 223) revealed enrichment for known MYCN up regulated
genes in focal gains and amplicons. Moreover, by applying an
integrated genomics approach including mRNA and miRNA
gene expression data and subsequent validation using MYCN and
miR-17,92 inducible cellular model systems, we identified
several genes, within the regions of focal loss, that are putatively
under the control of MYCN activated miRNAs. Of these, RGS5
and RNF11 were identified as two new MYCN regulated
therapeutically relevant genes, which are implicated in vascular
remodeling [13,14] and TGFß/NF-kß signaling [15–17],
respectively.
Results
Increased miR-17,92 copy number resulting from a focal
5 kb DNA copy number gain
High resolution array CGH analysis revealed, amongst others, a
5 kb focal gain of the miR-17,92 locus (13q31.3) in the MYCN
amplified cell line NLF (Figure 1A). FISH analysis showed the
presence of eight copies of the locus in this tetraploid cell line (data
not shown). Expression levels of the miR-17,92 cluster were
measured in 19 MYCN amplified and 8 MYCN non-amplified
neuroblastoma cell lines. As expected, the MYCN amplified cell
lines showed significantly increased miR-17,92 levels in keeping
with the previously described evidence for direct up regulation of
the cluster by MYCN [18,19]. MiR-17,92 expression levels are
not significantly higher in NLF cells as compared to the other
MYCN amplified cell lines, but MYCN expression is within the
lower range for NLF compared to the other MYCN amplified cell
lines (Figure 1B), in keeping with relatively lower level of MYCN
amplification (Figure S1). Therefore, we hypothesize that focal
copy number gain of the miR-17,92 locus and consequent
increased miR-17,92 expression levels due to dosage effect may
compensate for the relatively lower MYCN mRNA levels in cell
line NLF. In accordance with this assumption, miR-17,92
expression levels are indeed similar to the expression levels in
MYCN amplified cell lines with higher MYCN expression levels.
The observed focal gain of the miR-17,92 locus prompted us to
further characterize focal DNA gains, amplifications and (homo-
zygous) losses in a large series of primary neuroblastoma tumor
samples and cell lines.
Assessment of focal DNA copy number gains,
amplifications and (homozygous) losses in primary
neuroblastoma tumors and cell lines
A set of 33 neuroblastoma cell lines and 190 primary
neuroblastoma tumors, representative of all clinical and genetic
subtypes, was analyzed for focal DNA copy number aberrations
(Table S1). In total, 14 homozygous, 4 hemizygous (located on
chromosome X) deletions and 159 recurrent (present in at least 2
cases) focal (,2 Mb) heterozygous deletions as well as 118
amplifications and 22 recurrent focal gains were detected (Table
S2) affecting 93 different chromosomal regions (see Materials and
Methods for detailed description). Our analysis confirmed and
further documented previously reported homozygous deletions
involving several known tumor suppressor genes such as KIF1B
(1p36.22), CDKN2A/CDKN2B (9p21.3) and NF1 (17q11.2) as well
as previously described focal heterozygous losses harboring genes
such as APAF1 (12q23), ELAVL4 (1p34) and PTPRD (9p23-p24.3),
while several amplifications were observed targeting well estab-
lished oncogenes such as MYCN (2p24.1), ALK (2p23) and MDM2
(12q14.3-q15) [9,10,20–23] (Table S2). Unbiased functional
annotation analysis using the DAVID web tool [24] for genes
located within regions of focal DNA copy number alteration
revealed amongst others significant enrichment for pathways
involved in ‘‘cell cycle and division’’ (including e.g. CCND1,
CDKN1C, CDK4), ‘‘cellular apoptosis’’ (including e.g. CDKN2A,
DFFA, APAF1) and ‘‘protein kinase’’ (including e.g. INSR and
NF1). Given the implication of genes involved in activated
tyrosine kinase pathways in neuroblastoma, NF1 (a negative
regulator of RAS signaling, targeted by homozygous loss), INSR
and ITK (both tyrosine kinases, targeted by amplification) were
selected for mutation analysis in a panel of neuroblastoma cell
lines. Loss-of-function mutations in the NF1 gene were detected
in 23.5% of tested cell lines (confirming previous findings [10])
and a potentially damaging mutation in the ITK gene was
detected in the tyrosine kinase domain in cell line NBL-S. No
mutations were found for INSR (Table S1). Furthermore, we
carefully compared data from our study with the complete
genome sequencing data from Molenaar et al. (2012) [11] and
found a significant overlap of regions affected by focal gains and
losses including regions encompassing genes implicated in
neuritogenesis or neuronal development (Table S3). Finally,
when investigating the distribution of the focal gains and
amplifications across the genetic subtypes, we observed that
these focal aberrations occur more frequently in MYCN amplified
samples (subtype 1, 2.6%; subtype 2A, 5.4%; subtype 2B, 48.8%
(p(FE (2B vs 1)),1.0E-4, p(FE (2B vs 2A)),1.0E-4). Focal (homozygous)
deletions are also observed more frequently in MYCN amplified
samples, however this difference is not significant with subtype 2A
(subtype 1, 22.4%; subtype 2A, 24.3%; subtype 2B, 41.9% (p(FE
(2B vs 1)) = 3.6E-2; p(FE (2B vs 2A)) = 0.13) (Figure S2). When
combining all focal aberrations, a significantly higher frequency
was noted in subtype 2B tumors (p(FE (2B vs 1)),1.0E-4; p((FE (2B vs
2A)) = 1.9E-3).
Focal DNA copy number gains are enriched for up
regulated MYCN target genes
Further analysis showed that in addition to miR-17,92, several
known bona fide direct MYCN targets were affected by either gains
or high level amplifications. A first example is the TERT gene [25]
that was found for the first time as part of an amplified region at
5p15.33 in two MYCN non-amplified tumors (140 and 293 kb in
size). In addition, a focal gain of this locus was found in one
MYCN amplified primary tumor sample. DNA copy number
analysis of these samples using qPCR revealed the presence of up
to 41 TERT copies per haploid genome equivalent. Increased
TERT expression could be confirmed in one amplified sample for
which expression data were available, as compared to the tumors
without TERT amplification (data not shown). Other examples of
direct MYCN targets located within amplified regions in both our
data set and previously reported array CGH data sets include
CDK4 (in one MYCN amplified and one MYCN non-amplified
tumor and two MYCN amplified cell lines) and MDM2 (in two
MYCN amplified tumors and two MYCN amplified cell lines)
[23,26]. Of further interest, we observed several distinct regions on
chromosome 2 that were co-amplified with MYCN and harbor
direct MYCN target genes (i.e. E2F6, ODC1 and PPM1G) [25,27].
In particular, a region on chromosome 2 that is most often co-
amplified with MYCN as a separate amplicon (in 4/43 MYCN
Focal Aberrations in NB Comprise MYCN Target Genes
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amplified tumors (9.3%) and 2/24 MYCN amplified cell lines
(8.3%)) contains the bona fide oncogene ODC1 (2p25.1), which was
recently described as a critical determinant of MYCN oncogenesis
[28].
In a next step, we tested the regions of focal gain and
amplification for enrichment of up regulated MYCN target genes,
as available in the MYCNot database (http://medgen.ugent.be/
MYCNot). A separate analysis was performed (1) for the up
regulated target genes with a validated direct interaction with
MYCN (referred to as directly up regulated MYCN target genes)
and (2) for all up regulated genes in the MYCNot database,
meaning all indirect MYCN targets, putative direct MYCN targets
(for which currently no experimental proof is available) as well as
the above mentioned validated direct MYCN target genes.
Investigation of focal gains and amplicons in our sample panel
revealed significant enrichment for directly up regulated MYCN
target genes in high risk MYCN non-amplified (subtype 2A) and
MYCN amplified (subtype 2B) tumors as well as in the cell lines.
When performing this analysis for all up regulated MYCN target
genes listed in the MYCNot database, significant enrichment
could be seen for all tumor subtypes and cell lines (Table 1; Table
S3). Furthermore, we noticed that the regions containing direct
MYCN targets in subtype 2A tumors i.e 5p15 (TERT) and
12q13.2-q14.1 (CDK4) are also gained or amplified in subtype 2B
tumors (the indirect targets INHBE, NACA and SHMT2, also
located in the 12q13.2-q14.1 amplicon were not found gained or
amplified in the subtype 2B tumors).
Integrated genomic analysis for identification of genes
down regulated by MYCN driven miRNAs and located
within regions of focal genomic loss
Using the MYCNot database, no enrichment of MYCN down
regulated target genes could be observed in the focal deletions.
This was not unexpected, since so far only a limited number of
down regulated MYCN target genes have been carefully assessed
and validated. Recent studies revealed that MYCN-induced
miRNA activation acts as an important mechanism for indirect
down regulation of gene expression following MYCN overexpres-
sion [18,19,29]. We and others recently showed that DKK3 and
ESR1 as well as several TGFb pathway components were down
regulated as a result of increased levels of miRNAs encoded by the
miR-17,92 cluster in neuroblastoma [12,30,31]. Although for
these genes no focal deletions were observed, we hypothesized that
the deleted regions might encompass genes that are regulated by
MYCN driven miRNAs suggesting an alternative mechanism to
enforce MYCN downstream signaling, which thus far remained
unstudied. To investigate this hypothesis, we used an integrative
data mining approach that allows to pinpoint genes, located within
regions of focal copy number loss, which are potentially negatively
regulated by MYCN through MYCN driven miRNAs.
First, we investigated a cohort of 101 neuroblastoma samples for
MYCN status and expression levels of MYCN activated miRNAs
(as listed by Mestdagh et al. 2010 [18]) in relation to the mRNA
expression level of each gene located within a focal loss. Candidate
genes were defined as genes with expression levels significantly
lower (p,5.0E-2) in MYCN amplified compared to MYCN non-
Figure 1. Focal gain of the MYCN activated miR-17,92 cluster and expression levels in neuroblastoma cell lines. A. High resolution
array CGH analysis shows a 5 kb focal gain for the miR-17,92 locus (13q31.3) in the MYCN amplified cell line NLF. B. Expression levels of MYCN (left)
and the miR-17,92 cluster (right) in 8 MYCN non-amplified and 18 MYCN amplified neuroblastoma cell lines as compared to the MYCN amplified NLF
cell line.
doi:10.1371/journal.pone.0052321.g001
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amplified samples and that showed a significant negative
correlation (p,5.0E-2) to the expression of at least one MYCN
driven miRNA for which there was at least one 6-mer seed region
present in the 39UTR of the gene. Candidate genes were first
ranked according to the lowest p-value representative for lower
expression in MYCN amplified versus MYCN non- amplified
samples and subsequently to the highest number of significant
negative correlations to the expression of MYCN driven miRNAs
(Table 2). This analysis generated a list of 38 candidate genes. Of
interest, this selection contained genes present in 5 out of 10
regions of homozygous loss found in our study and several genes
known to be implicated in cancer and neuronal differentiation
(such as NF1 and GAP43).
In a next step, we sought further evidence for MYCN driven
regulation of these candidate genes using the SHEP-TET21-N-
MYC inducible model system [27,32]. Nine candidate genes were
significantly down regulated upon MYCN induction in this cell
line marking these genes as potential candidates for down
regulation by MYCN driven miRNAs. In order to find evidence
for possible MYCN driven miRNA mediated down regulation, we
further tested these genes in a second inducible model system for
miR-17,92 overexpression (SHEP-TR-miR-17,92 model sys-
tem; [12]). Upon miR-17,92 induction, 4 out of 38 genes showed
down regulation of which 2, RGS5 and RNF11, were also down
regulated after MYCN induction. Down regulation was confirmed
for both genes by qPCR (Figure S3). Survival analysis in the same
cohort of 101 neuroblastoma tumors showed association of
decreased mRNA expression levels of both RGS5 and RNF11
with poor survival (p = 4.8E-2; p = 6.4E-4), which is in line with
the observed association of both genes with MYCN expression.
RNF11 was recently shown to be regulated by the miR-19b
component of the miR-17,92 cluster [15] in keeping with the
above findings.
The homozygously deleted RGS5 gene is a newly
identified indirect MYCN down regulated gene
RGS5 is homozygously deleted on chromosome 1q23 in cell line
NLF. Using ultra-high density (1M) oligo array CGH breakpoints
of this 27 kb deletion were further delineated and complete loss of
RGS5 expression was confirmed by qPCR (Figure S4). In a next
step, we further investigated the presumed regulation of RGS5 by
the MYCN induced miR-17,92 cluster. There was no evidence
for direct down regulation of RGS5 by MYCN based on MYCN
chromatin immunoprecipitation (ChIP) sequencing data of four
neuroblastoma cell lines (data not shown). Furthermore, given the
presence of multiple seed regions of MYCN driven miRNAs in the
RGS5 39UTR and significant negative correlation between RGS5
expression and seven of these miRNAs (Table S4), we evaluated
their repressive effect on RGS5 expression. We selected four of the
seven MYCN driven miRNAs (p,5.0E-2): miR-9, miR-20a, miR-
92a and miR-181a and tested binding to the 39UTR of RGS5. To
this purpose, HEK-293T cells were co-transfected with a 39UTR
luciferase reporter plasmid, containing the full length 5074 bp
RGS5 39UTR, and the selected pre-miRs. This showed significant
decrease in luciferase activity for miR-20a, miR-92a and miR-
181a indicating a direct interaction between these miRNAs and
the 39UTR of RGS5 (Figure 2A). No evidence for binding was
obtained for miR-9 thereby excluding 39UTR-mediated direct
regulation of RGS5 expression for this miRNA. Mutation of the
active 7mer miRNA seed regions for miR-92a and two 6mer seeds
for miR-20a allowed to rescue the luciferase output in keeping
with the assumption that the effect on luciferase reduction depends
on the presence of the active miRNA seed sequences in the
39UTR of RGS5 (Figure 2B). A rescue effect after mutation of the
7mer seed for miR-181 could not be observed. RGS5mRNA down
regulation following miR-17,92 induction in the SHEP neuro-
blastoma cell line (SHEP-TR-miR-17,92; [12]) is in keeping with
the above described direct interaction between two members of
the miR-17,92 cluster, i.e. miR-20a and miR-92a and the 39UTR
of RGS5 (fold change= 1.53).
In addition to posttranscriptional down regulation, we also
investigated the possibility that RGS5 might be targeted by loss-of-
function mutations but sequencing of a panel of cell lines revealed
no mutations, in keeping with low mutation rate in neuroblastoma
[11], which was published following our RGS5 sequencing
analysis.
Discussion
MYCN is a crucial driver gene in the childhood cancer
neuroblastoma as illustrated by overexpression due to genomic
amplification in a large subset of high risk tumors and formation of
neuroblastoma in MYCN-driven transgenic mouse and zebrafish
model systems [33–37]. The recently demonstrated functional and
synergistic relationship between MYCN and ALK, another
important oncogene in neuroblastoma, further reinforces the
central role of MYCN in neuroblastoma oncogenesis [35,38–40].
With the exception of ALK, for which activating mutations are
observed in 7% of tumors, single nucleotide substitutions are rarely
observed in neuroblastoma [11]. Thus far, the genomic landscape
of neuroblastoma seems to be dominated by DNA copy number
alterations and chromothripsis, for the latter the functional
consequence remains to be established. Combined analysis of
rare mutations and focal DNA copy number changes provided
Table 1. Enrichment analysis for (direct) MYCN target genes in focal aberrations in the clinico-genetic neuroblastoma tumor
subgroups and cell lines.
p-value all (n = 223) 1 (n =76) 2A (n =37) 2B (n =43) cell lines (n=33)
direct MYCN targets
target up - gene gain 0.087 1 0.012* 0.026* 9.5E-3*
target down - gene deletion 1 1 1 1 1
all MYCN targets
target up - gene gain 1.81E-6* 0.031* 0.030* 4.12E-5* 3.28E-7*
target down - gene deletion 1 0.411 0.410 0.233 0.728
*significant p-value (p,0.05).
‘‘all’’ includes also unclassified tumor samples (n = 34).
doi:10.1371/journal.pone.0052321.t001
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evidence for their functional relevance to the tumor cell given the
implications of many of these genes in the control of normal
neuritogenesis [11]. Here, we add further evidence for selective
advantage for tumor cells exhibiting focal gains and losses
encompassing genes under direct or indirect transcriptional
control of MYCN (Figure 3). First, we observed in cell line NLF
a focal gain of miR-17,92, an important oncogenic locus under
the direct transcriptional control of MYCN. In this cell line,
MYCN is amplified but with moderate increased copy number
levels. In keeping with this observation, MYCN mRNA expression
is clearly elevated but within the lower range of the cohort of
MYCN amplified cell lines. We therefore hypothesize that miR-
17,92 copy number gain may have been selected to reinforce the
MYCN-driven oncogenic phenotype in this cell line as this
miRNA cluster is a well-established direct oncogenic target of
MYCN and MYC and is consistently up regulated inMYCN/MYC
amplified neuroblastoma as well as in other tumor entities [18,41].
Further investigation of a large array CGH data set of
neuroblastomas confirmed several previously reported rare recur-
rent amplicons. These regions contain bona fide up regulated
MYCN target genes such as ODC1, TERT, CDK4 and MDM2
(Figure 3) [23,25,26,28]. Using the MYCNot database, we found
enrichment of both directly and indirectly up regulated MYCN
target genes in the focal DNA copy number gains. Encouraged by
these findings, we also explored the genes that were targeted by
focal deletions. Using an integrated genomics approach by
combining DNA copy number data, mRNA and miRNA gene
expression data as well as miRNA seed information, we selected 38
candidate genes for down regulation by MYCN activated
miRNAs. Using a MYCN and miR-17,92 inducible cell line
model system, we identified two new genes regulated by
components of the MYCN regulated miR-17,92 cluster, i.e.
RGS5 and RNF11 (Figure 3). RGS5 encodes for a negative
regulator of G-protein signaling implicated in vascular normali-
zation, invasion and metastasis and its involvement was shown in
breast and lung cancer. More specifically, reduced expression of
RGS5 was associated with increased tumor aggressiveness and
poor survival in keeping with our observations in NB
[13,14,42,43]. The in vivo role of RGS5 in neuroblastoma tumor
vascularity is currently under further investigation.
RNF11 is an important regulator of TGFb, EGFR and NF-kb
signaling and mediates the ubiquitination and proteolysis of many
cellular proteins [15,17,44]. The role of RNF11 in the TGFb
pathway is of particular interest in neuroblastoma given our
previous finding that the miR-17,92 cluster components target
TGFBR2 and SMAD2 as well as TGFb downstream regulated
genes CDKN1A, ITGA4, and SERPINE1 [12]. RNF11 enhances
TGFb signaling through rescue of SMAD2 from degradation and
by blocking the activity of SMURF2, the latter that interacts with
inhibitory SMADs to target the TGFb receptor for destruction via
proteasomal degradation. RNF11 can also bind directly to
SMAD4 and directly regulate SMAD4 transcriptional activity
[16,17]. It should be noted that SMURF2 is located on 17q24.1,
one of the most frequently affected regions by partial and whole
chromosome gains in neuroblastoma. Further studies are neces-
sary to explore the possible interaction between MYCN/MYC up
regulation and SMURF2 copy number gains in neuroblastoma in
relation to suppression of TGFb signaling.
The present study investigates gene content of focal gains,
amplicons and deletions in neuroblastoma. Interestingly, these
focal aberrations occur more frequently in MYCN amplified
tumors (this study) whereas a higher frequency of large segmental
aberrations was observed in subtype 2A tumors in keeping with
previously published data [45]. Most of the more frequent gains
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and amplifications contain known bona fide oncogenes such as
ODC1 (n = 7; 3.1%) [28], CDK4 (n = 4; 1.8%) [46,47], MDM2
(n = 4; 1.8%) [48,49] and ALK (n = 4; 1.8%) [39,50]. Several of the
more frequent deletions (including homozygous ones) harbor
known tumor suppressor genes such as CDKN2A (n = 4; 1.8%)
[51,52], NF1 (n = 5; 2.2%) [10], PTPRD (n = 5; 2.2%) [53,54] and
genes involved in apoptosis such as APAF1 (n = 4; 1.8%) [55], IKIP
(n = 4; 1.8%) [56], WWOX (n = 4; 1.8%) [57,58] and FAF1 (n = 4)
[59]. Importantly, this study provides further evidence that
(recurrent) focal genomic alterations contribute to the cancer cell
phenotype through reinforcing the effects of multiple components
of a single pathway as recently illustrated for the p53 and cell cycle
pathway in diffuse large B cell lymphoma [60] and for the
NOTCH pathway in T-ALL [61]. More specifically, we show here
that a significant proportion of such focal copy number changes
target genes implicated in MYCN signaling and may therefore
reinforce the oncogenic effect of MYCN (or MYC) on neuroblas-
toma cells. Interestingly, this observation is also in line with other
genomic alterations targeting upstream regulators of MYCN
activity (Figure 3). Recently, mutant and wild type ALK was
shown to directly regulate MYCN transcription levels [40,62] and
increase MYCN protein stability through PI3K/AKT driven
phosphorylation of S62 [63,64]. Of further notice, LIN28B, a
negative regulator of the let-7 family of miRNAs targeting MYCN
mRNA, was amplified in rare neuroblastoma cases and more
recently transgenic mice overexpressing LIN28B in the developing
sympathetic nervous tissue were shown to develop neuroblastoma
[65–67]. Therefore, a picture is emerging of a darwinistic genetic
wiring in neuroblastoma cells in which multiple events strive to
increase MYCN downstream activity.
Materials and Methods
Tumor samples and cell lines
A series of 190 primary neuroblastoma tumor samples was
collected prior to therapy (56 cases from Ghent University
Hospital, Belgium, 33 from the Medical School of Valencia,
Spain and 101 from Essen University Children’s Hospital,
Germany) for which a written informed consent was obtained
and approved by the commision for medical ethics of the
Figure 3. Rare recurrent focal copy number changes in neuroblastoma target up and downstream MYCN pathway components.
Illustration of genes in focal genomic gains (light green) and amplifications (dark green) that are direct up regulated MYCN target genes or upstream
regulators of MYCN and genes in focal heterozygous (light red) and homozygous (dark red) deletions which are down regulated by MYCN through its
activated miRNAs. Protein structure was obtained from www.pdbe.org.
doi:10.1371/journal.pone.0052321.g003
Figure 2. miRNA interaction with the 39UTR of RGS5. A. Relative luciferase activity obtained by transfecting cells with the wild type 39UTR of
RGS5 in combination with pre-miR-negative control (NTC), pre-miR-20a, pre-miR-92a and pre-miR-181a in HEK293T cells. B. Relative luciferase activity
obtained by transfecting cells with mutated 39UTR of RGS5 in combination with pre-miR-NTC, pre-miR-20a, pre-miR-92a and pre-miR-181a in
HEK293T cells.
doi:10.1371/journal.pone.0052321.g002
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respective institutions (#08-3670; EC/2006-146/Svdm; EC/
2007-137/Svdm; 2010/037). In addition, 33 neuroblastoma cell
lines were included in this study. Patient and cell line information
(including cell line references) are summarized in Table S1. DNA
was isolated from primary tumors and cell lines using the Qiagen
DNA isolation kit (Qiagen, Cat nr 51304) according to the
manufacturer’s instructions. Total RNA was isolated using the
miRNeasy kit (Qiagen) according to the manufacturer’s instruc-
tions including DNase treatment on column. miRNA and mRNA
expression data of 101 tumors was previously published [12,18]
and data is available at the Gene Expression Omnibus (GEO,
http://www.ncbi.nlm.nih.gov/geo/ accession number:
GSE32664).
Array Comparative Genomic Hybridization (array CGH)
and data analysis
Samples were profiled on a custom designed 44K (156 samples),
60K (66 samples) or 180K (1 sample) array (Agilent Technologies)
enriched for critical regions in neuroblastoma (1p, 2p, 3p, 11q, 17),
cancer gene census genes [68], non-coding sequences (miRNAs
and transcribed ultra-conserved regions) and all genes from the
Neuroblastoma Gene Server (NBGS) database [69]. The latter
database contains curated lists of differentially expressed genes
retrieved from all major published high-throughput neuroblasto-
ma gene expression profiling studies. Validation experiments were
performed on the commercially available 1M array (Agilent
Technologies). The array designs are based on the hg18 genome
build. Utilizing random prime labeling (BioPrime ArrayCGH
Genomic Labeling System, Invitrogen), 400 ng (44K/180K),
200 ng (60K) or 1 mg (1M for validation purposes) of tumor and
control DNA was labeled with Cy3 and Cy5 dyes (Perkin Elmer),
respectively. Further processing was then performed according to
the manufacturer’s instructions (Agilent Technologies). Fluores-
cence intensities were measured using an Agilent scanner
(G2505C, Agilent Technologies). Data were extracted using the
Feature Extraction v10.1.1.1 software program (Agilent Technol-
ogies) and further processed with arrayCGHbase (http://medgen.
ugent.be/arraycghbase) [70]. Array CGH profiles were further
processed using the ‘‘no waves’’ [71] and the circular binary
segmentation (CBS) algorithm [72] that splits the genomic data
into contiguous regions of equal copy number, and uses
permutation to define copy number abnormalities at a defined
significance level. The statistical environment R (version 2.10.0)
was used to identify the location of all possible amplifications,
homozygous deletions and recurrent focal gains and losses,
whereas gene information was extracted using BioMart [73] and
then used to determine the genes residing within these regions.
The miRBase database was used to extract the chromosomal
locations of the miRNAs and to identify in which regions these
reside. The following criteria were used to select copy number
alterations (CNA) inferred by DNA copy number analysis for
further validation and study: (a) homozygous deletion (log2(CBS
value),22.0), (b) amplification (log2(CBS value).2.0), (c) focal
recurrent loss and (d) focal recurrent gain. We defined focal losses
and gains for (c) and (d) as alterations ,2 Mb involving at least 2
non-overlapping contiguously altered oligos (log2(CBS value),20.3
and .1.0, respectively). Since we aimed to find genes important in
neuroblastoma biology we looked for recurrent alterations defined
by their occurrence in at least 2 samples. Chromosomal regions
that are homozygously deleted or amplified (.8 haploid copies)
are typically small and very likely to contain tumor suppressor
genes and oncogenes, respectively. Therefore, all (and not only
recurrent) homozygously deleted regions or amplicons were taken
into account for further analysis. Throughout the text we will refer
to (a) and (c) as focal copy number losses and to (b) and (d) as focal
copy number gains. The Y chromosome was excluded from the
analysis. Copy number variants characteristic for control DNAs
were excluded. Aberrations that were present in more than 5 cases
in a separate in-house screened clinical genetics cohort of 1000
samples were considered as possible copy number variants and
excluded from further analysis (http://medgen.ugent.be/
arraycghbase). All reported results were confirmed by manual
inspection of the array profiles. All homozygous deletions,
amplifications and focal recurrent losses and gains that met the
aforementioned criteria are provided in Table S2. Thirty-eight
regions were tested for validation using FISH, qPCR or ultra-high
resolution oligonucleotide arrays and aberrations could be
confirmed for 33 regions (87%) (Table S2). All array data are
available at http://medgen.ugent.be/arraycghbase (login: guest,
password: guest).
MYCN oncogene targets (MYCNot) database
To summarize the current knowledge on MYCN downstream
cascades, a thorough literature search was performed to track
down all hitherto identified MYCN downstream genes. We
grouped all the information and assembled and annotated the
individual genes into the ‘MYCN oncogene targets’ (MYCNot)
database (http://medgen.ugent.be/MYCNot). Most of the genes
listed in the database have been identified as putative MYCN
target genes through one or more differential expression screens
without any other evidence suggesting that they are directly
regulated by MYCN alone or by both MYCN and other
transcription factors that work in a co-ordinated manner.
Currently, 1041 up and down regulated MYCN mRNA targets
are included in this database.
Real-Time quantitative Polymerase Chain Reaction
(qPCR)
Real-Time qPCR was performed for validation of DNA CNAs
and for expression evaluation. DNA and RNA concentration was
measured using the Nanodrop (Thermo Scientific). First-strand
cDNA was synthesized from total RNA using an iScript cDNA
synthesis kit (Bio-Rad). qPCR reactions were performed with
SYBR Green I detection chemistry, using the LC480 real-time
PCR detection system (Roche). qPCR reactions were performed in
a total volume of 5 ml consisting of 2.5 ml of SYBR Green I qPCR
master mix (26) (Eurogentec, HotGoldStar polymerase), 0.25 ml of
forward and reverse primer (5 mM), 2 ml of 2.5 ng/ml DNA or
cDNA (total RNA equivalents). Cycling conditions were as follows:
10 minutes at 95uC followed by 45 cycles of 10 seconds at 95uC,
45 seconds at 60uC and 1 second at 72uC. DNA copy number
levels were measured relative to human genomic DNA (Roche
Diagnostics) and normalized to the internal reference genes,
BMCA (ID 14) and SDC4 (ID 15). mRNA expression levels were
measured and normalized to at least 2 internal reference genes,
TBP (ID 8098), YWHAZ (ID 8100), B2M (ID 2) and UBC (ID
8099). Primer sequences are available in RTPrimerDB (http://
www.rtprimerdb.org) [74], ie hsa-miR26a-2 (ID 8243), hsa-miR-766
(ID 8250), RGS5 (ID 8244), TCF4 (ID 8245), ITK (ID 8246), INSR
(ID 8247), TERT (ID 8248), SEPT6 (ID 8249) CDKN2A (ID 8251),
NF1 (ID 8252), DIAPH2 (ID 8254), IGSF6 (ID 8255), THRAP3 (ID
8257), A2BP1 (ID 8258), MYCN (ID 11), RGS5 (ID 8261-
expression) and RNF11 (ID 8592-expression). Copy number and
mRNA data analysis as well as error propagation was done using
qbasePLUS software 1.5 (http://www.biogazelle.com) [75]. All
real-time qPCR assays were conducted in duplicate.
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Expression analysis of neuroblastoma cellular model
systems and cell lines
SHEP-TET21N-MYC cells were cultured in RPMI (Invitrogen)
supplemented with 10% fetal calf serum and treated with 1 mg/ml
tetracycline (Sigma-Aldrich) to switch off MYCN expression (as
reported in [32]). Publically available expression data from
tetracycline treated and untreated SHEP-TET21N-MYC cells
[32] were downloaded from the ArrayExpress website (accession
number E-MEXP-2340) and validated for selected markers using
qPCR. SHEP-TR-miR-17,92 cells were cultured in RPMI
(Invitrogen) supplemented with 10% fetal calf serum and treated
with 2 mg/ml tetracycline (Sigma-Aldrich) to induce miR-17,92
expression as reported in [18]. Expression data from the
tetracycline treated and untreated miR-17,92 inducible neuro-
blastoma SHEP cell line system were analysed using Affymetrix
GeneChip Human Gene 1.0 ST arrays [18] (Table S5). Fold
changes larger than 1.2 were considered potentially relevant in this
model system and were subsequently validated using qPCR.
MYCN and miR-17,92 expression level were determined for 27
neuroblastoma cell lines for which gene expression profiling was
performed using Sureprint G3 human gene expression micro-
arrays (Agilent Technologies) according to the manufacturer’s
instructions as well as miRNA profiling using a stemloop RT-
qPCR platform as described previously [76,77] (Table S6).
Statistics
Statistical analyses were performed with the statistical environ-
ment R. Enrichment analyses were done using a Fisher exact (FE)
test. For the prioritization of genes in focal losses, selection of the
candidate genes was performed by combining data of spearman
correlation analysis between miRNA and mRNA expression data
and paired t-test. Statistical significance was defined as p,5.0E-2.
Sequencing
Sequence analysis of the coding exons and flanking intronic
sequences of RGS5 and the tyrosine kinase domain of ITK was
performed on genomic DNA. NF1 (using emetin treated material
[78]) and the tyrosine kinase domain of INSR were sequenced on
the cDNA level. PCR products were subjected to unidirectional
sequencing using BigDye Terminator V1.1/V3.1 Cycle Sequenc-
ing chemistry using an ABI3730XL sequencer (Applied Biosys-
tems). Electropherograms were analyzed using Seqscape v2.5
software (Applied Biosystems). Primer info is summarized in Table
S7.
39UTR luciferase assay
The 39UTR of the human RGS5 gene was cloned in a vector
downstream of the firefly luciferase open reading frame (pMir-
Target vector, Origene). Seed regions were mutated using the
QuickChange II mutagenesis kit (Stratagene). Specifically, the
complementary sites of miR-20a (2), miR-92a and miR-181a,
CCACACATACACACACACACTTTTTGTTTCTTTCAGG-
TAGAC and CTGTTTGTGTTAAACACACTTTTCACCAA-
ATAGGTTC, TATTCACATTATTTGCAATATCCAAATG-
TTTAAAAATTC and GACTATGATATCAATGAATGTGG-
GTTAAGTAATAG were changed into CCACACATACACA-
CACAAAAGGTTTGTTTCTTTCAGGTAGAC and CTGTT-
TGTGTTAAACAAAAGGTTCACCAAATAGGTTC, TATT-
CACATTATTGGACCTATCCAAATGTTTAAAAATTC and
GACTATGATATCAAGGCCGGTGGGTTAAGTAATAG, re-
spectively. HEK-293T cells were plated at 10,000 cells per 96-well
in RPMI medium containing 10% FBS 24 hrs prior to transfec-
tion. Transfection mixes contained RPMI medium, 50 nM pre-
miR (Applied Biosystems), 0.4% DharmaFect Duo (Dharmacon)
and 100 ng oligo-psiCHECK vector. The ratios between Firefly
and Renilla luciferase were measured 48 hr post-transfection using
the dual-glo luciferase kit (Promega) according to the manufac-
turer’s protocol.
Supporting Information
Figure S1 MYCN copy number and gene expression for
neuroblastoma cell lines. MYCN copy number data (log2) and
MYCN expression data were plotted for a panel of MYCN
amplified and MYCN non-amplified cell lines. MYCN expression
levels were significantly higher in the MYCN amplified cell lines
(**; p(Mann-Whitney),0.001). A linear relation was observed between
MYCN copy number and expression within the group of MYCN
amplified cell lines (p,0.005).
(TIF)
Figure S2 Distribution of focal aberrations. A. Distribu-
tion of recurrent focal gains and amplifications and B. recurrent
focal losses and homozygous deletions in the neuroblastoma
tumors according to subtype. Amplification of the MYCN locus
was excluded for this analysis as MYCN amplification is
characteristic of subgroup 2B. ***, p(FE),0.0001; *, p(FE),0.05
(TIF)
Figure S3 Confirmation of RGS5 and RNF11 down
regulation. A. Confirmation of RGS5 and RNF11 down
regulation using qPCR after induction of MYCN in the SHEP-
TET21-N-MYC and B. miR-17,92 in the SHEP-TR-miR-
17,92 inducible model systems.
(TIF)
Figure S4 Confirmation of RGS5 homozygous deletion
in NLF. A. Confirmation of RGS5 homozygous deletion by 1M
high-resolution array CGH. B. RGS5 mRNA expression by qPCR
in NLF versus average expression in NB cell lines.
(TIF)
Table S1 Overview of patient and cell line information.
(XLSX)
Table S2 Overview of focal aberrations in tumors and
cell lines.
(XLSX)
Table S3 Detail of enrichment analyses.
(XLSX)
Table S4 Correlation of MYCN regulated miRNAs to
RGS5 and RNF11 expression and miRNA seed informa-
tion.
(XLSX)
Table S5 Fold change data from the tetracycline treated
and untreated SHEP-TR-miR-17,92 inducible model
using Affymetrix GeneChip Human Gene 1.0 ST arrays
[18].
(XLSX)
Table S6 MYCN amplification status and expression
and miR-17,92 expression in a panel of neuroblastoma
cell lines.
(XLSX)
Table S7 List of sequencing primers.
(XLSX)
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